Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||The amyloid precursor protein derivative, APP96-110, is efficacious following intravenous administration after traumatic brain injury|
Den Heuvel, C.
|Citation:||PLoS ONE, 2018; 13(1):e0190449-1-e0190449-16|
|Publisher:||Public Library of Science (PLoS)|
|Stephanie L. Plummer, Frances Corrigan, Emma Thornton, Joshua A. Woenig, Robert Vink, Roberto Cappai, Corinna Van Den Heuvel|
|Abstract:||Following traumatic brain injury (TBI) neurological damage is ongoing through a complex cascade of primary and secondary injury events in the ensuing minutes, days and weeks. The delayed nature of secondary injury provides a valuable window of opportunity to limit the consequences with a timely treatment. Recently, the amyloid precursor protein (APP) and its derivative APP96-110 have shown encouraging neuroprotective activity following TBI following an intracerebroventricular administration. Nevertheless, its broader clinical utility would be enhanced by an intravenous (IV) administration. This study assessed the efficacy of IV APP96-110, where a dose-response for a single dose of 0.005mg/kg- 0.5mg/kg APP96-110 at either 30 minutes or 5 hours following moderate-severe diffuse impact-acceleration injury was performed. Male Sprague-Dawley rats were assessed daily for 3 or 7 days on the rotarod to examine motor outcome, with a separate cohort of animals utilised for immunohistochemistry analysis 3 days post-TBI to assess axonal injury and neuroinflammation. Animals treated with 0.05mg/kg or 0.5mg/kg APP96-110 after 30 minutes demonstrated significant improvements in motor outcome. This was accompanied by a reduction in axonal injury and neuroinflammation in the corpus callosum at 3 days post-TBI, whereas 0.005mg/kg had no effect. In contrast, treatment with 0.005m/kg or 0.5mg/kg APP96-110 at 5 hours post-TBI demonstrated significant improvements in motor outcome over 3 days, which was accompanied by a reduction in axonal injury in the corpus callosum. This demonstrates that APP96-110 remains efficacious for up to 5 hours post-TBI when administered IV, and supports its development as a novel therapeutic compound following TBI.|
|Keywords:||Animals; Rats; Rats, Sprague-Dawley; Amyloid beta-Protein Precursor; Male; Administration, Intravenous; Brain Injuries, Traumatic|
|Rights:||© 2018 Plummer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Appears in Collections:||Medicine publications|
Files in This Item:
|hdl_111069.pdf||Published version||2.99 MB||Unknown||View/Open|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.